Joseph O’Connell - Concepedia

Author

Joseph O’Connell

Also Known As

J O'Connell, J P O'Connell, J. O'Connell, J. O’Connell, J. P. O'Connell, J.P. O'Connell, JP O'Connell, Joseph O'Connell, Joseph O’Connell, Joseph P. O'Connell

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Dana-Farber Cancer Institute Memorial Sloan Kettering Cancer Center Pfizer (China)Emory University

About

Joseph O’Connell is an author at Pfizer (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	24	1.9K
2	Health Sciences	5	5	387
3	Cell Biology	4	4	390
4	Public Health	1	1	44
5	Allergy	1	1	56

Joseph O’Connell

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. Mark G. Kris, Richard J. Gralla, R A Clark, Journal of Clinical Oncology Cisplatin AdministrationHigh-dose CisplatinMedicineDelayed EmesisPharmacology	1985	341
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors Mark G. Kris, D. Ross Camidge, Giuseppe Giaccone, Annals of Oncology Her2 AberrationsLung CancersOncologyActionable DriversMedicine	2015	323
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer Suresh S. Ramalingam, Fiona Blackhall, Maciej Krzakowski, Journal of Clinical Oncology	2012	265
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. Joseph O’Connell, Mark G. Kris, Richard J. Gralla, Journal of Clinical Oncology Advanced NsclcCombination ChemotherapyMedicineCancer ManagementPretreatment Clinical Characteristics	1986	241
A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge, Cancer	2014	142
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial Suresh S. Ramalingam, Pasi A. Jänne, Tony Mok, The Lancet Oncology Dacomitinib Versus ErlotinibNon-small-cell Lung CancerMedicinePathologyImmune Checkpoint Inhibitor	2014	134
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial Pasi A. Jänne, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, The Lancet Oncology MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer Treatment	2014	123
Phase I trial of taxol given as a 3-hour infusion every 21 days. Mark G. Kris, Joseph O’Connell, Richard J. Gralla, PubMed Therapeutic Drug MonitoringMedicinal ChemistryOncologyUnique Plant ProductPharmacology	1986	96
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results Timothy A. Yap, Elisa Fontana, Elizabeth K. Lee, Nature Medicine	2023	94
Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer Mark G. Kris, R. Gralla, M. S. Wertheim, Lung Cancer MedicineBronchial NeoplasmCancer TreatmentPulmonary BlastomaOncology	1987	79

Page 1